[1]邓旭,王晓亮.肝细胞癌患者血清趋化因子CXCR12和SA的表达及临床意义[J].现代检验医学杂志,2015,30(06):49-51.[doi:10.3969/j.issn.1671-7414.2015.06.014]
　DENG Xu,WANG Xiao-liang.Expression and Clinical Significance of Serum CXCR12 and SA in Patients with Hepatocarcinoma[J].Journal of Modern Laboratory Medicine,2015,30(06):49-51.[doi:10.3969/j.issn.1671-7414.2015.06.014]
点击复制

肝细胞癌患者血清趋化因子CXCR12和SA的表达及临床意义()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第30卷
期数:
2015年06期
页码:
49-51
栏目:
论著
出版日期:
2015-12-30

文章信息/Info

Title:
Expression and Clinical Significance of Serum CXCR12 and SA in Patients with Hepatocarcinoma
作者:
邓旭; 王晓亮
榆林市第一医院，陕西榆林719000
Author(s):
DENG Xu; WANG Xiao-liang
the First Hospital of Yulin City,Shaanxi Yulin 719000,China
关键词:
肝细胞癌; 趋化因子CXCR12; 唾液酸
分类号:
R735.7；R730.43
DOI:
10.3969/j.issn.1671-7414.2015.06.014
文献标志码:
A
摘要:
目的探讨血清中趋化因子CXCR12和唾液酸SA在肝细胞癌中的表达及临床意义。方法应用酶联免疫吸附试验(ELISA)检测86例肝细胞癌患者血清趋化因子CXCR12和SA的表达水平，并与30例肝脏良性病变患者和23例健康对照者比较，分析其与肿瘤大小、TNM分期、分化程度、淋巴结转移以及AFP表达量的关系。结果肝细胞癌患者血清CXCR12表达量为5 362.52±985.43 pg/L，明显高于肝脏良性病变组(2 784.46±976.33 pg/L)和健康对照组(2 768.89±980.42 pg/L)，差异均具有统计学意义(t=352.15，387.77，P<0.05)，而肝脏良性病变组与健康对照组比较差异无统计学意义(t=1.80，P>0.05)；肝细胞癌患者血清SA的表达量为728.22±169.43mg/L，明显高于肝脏良性病变组(569.16±87.66mg/L)和健康对照组(564.26±89.23mg/L)，差异均具有统计学意义(t=56.48，61.53，P<0.05)，而乳腺良性病变组与健康对照组比较差异无统计学意义(t=1.88，P>0.05)。相关分析显示肝细胞癌患者血清CXCR12和SA水平之间呈正相关(r＝0.634，P<0.05)。肝细胞癌患者血清CXCR12和SA的表达水平与肿瘤大小、淋巴结转移、AFP水平及TNM分期明显相关(P<0.05)，但与肿瘤分化程度无明显相关性(P>0.05)。结论CXCR12和SA可能在肝细胞癌的发生发展中起着重要作用，两者联合检测对于肝细胞癌的辅助诊断、疗效监测及预后判断具有一定的临床意义。
Abstract:
ObjectiveTo evaluate the expression and its clinical significance of serum CXCR12 and SA in patients with hepatocarcinoma．Methods86 patients with hepatocarcinoma，30 patients with benign hepatic diseases and 23 healthy controls were recruited in this study．The CXCR12 and SA levels were measured by ELISA in the serum of 86 patients with hepatocarcinoma，30 patients with benign hepatic diseases and 23 healthy controls．ResultsThe level of serum CXCR12 in the hepatocarcinoma group (5 362.52±985.43pg/L) was significantly higher than those in benign hepatic diseases (2 784.46±976.33pg/L) and healthy controls (2 768.89±980.42pg/L) (t=352.15，387.77，P<0.05)．The level of serum SA　in the hepatocarcinoma group (728.22±169.43mg/L) was significantly higher than those in benign hepatic diseases (569.16±87.66mg/L) and healthy controls (564.26±89.23mg/L) (t=56.48，61.53，P<0.05)．No obvious difference in the levels of CXCR12 and SA was observed between benign hepatic diseases group and healthy control group (t=1.80，1.88，P>0.05)．Correlation analysis showed a positive correlation between the levels of CXCR12 and SA (r＝0.634，P<0.05)．The levels of serum CXCR12 and SA were significantly associated with tumor size，lymph node metastasis，the expression of AFP and TNM stage (P<0.05)，but were not associated with tumor differentiation (P>0.05)．ConclusionCXCR12 and SA play a role in the tumorigenesis and development of hepatocarcinoma．Measuring of serum CXCR12 and SA may be a useful tool for diagnosis，effect monitoring and prognosis in hepatocarcinoma．

参考文献/References:

［1］段秀枝，陶志华．肝癌的实验室标志物检测现状与展望［J］．中华检验医学杂志，2014，37(2)：84-86． Duan XZ，Tao ZH．The current status and future prospects of laboratory biomarkers in the diagnosis of liver cancer［J］．Chin J Lab Med，2014，37(2)：84-86．
[2]Torre LA，Bray F，Siegel RL，et al．Global cancer sta-tistics，2012［J］．CA：Cancer Journal for Clinicians，2015，65(2)：87-108．
[3]Suh DH，Lee KH，Kim K，et al．Major clinical research advances in gynecologic cancer in 2014［J］．Journal of Gynecologic Oncology，2015，26(2)：156-167．
[4]Xu QH，Wang Z，Chen X，et al．Stromal-derived factor-1α/CXCL12-CXCR4 chemotactic pathway promotes perineural invasion in pancreatic cancer［J］．Oncotarget，2015，6(7)：4717-4732．
[5]郑福利，党淼，张淼芳，等．子宫内膜癌组织中趋化因子CXCL12及其受体CXCR4表达水平研究［J］．现代检验医学杂志，2015，30(4)：21-23，27． Zheng FL，Dang M，Zhang MF，et al．Expression of chemokine CXCL12 and its receptor CXCR4 in endometrial carcinoma tissue［J］．J Mod Lab Med，2015，30(4)：21-23，27．
[6]田亚平，齐军，高春芳，等．血清唾液酸临床应用价值和临床研究中应重视的问题［J］．中华检验医学杂志，2013，36(10)：880-882． Tian YP，Qi J，Gao CF，et al．Some interesting questions about the clinical significance and future research on serum sialic acid［J］．Chin J Lab Med，2013，36(10)：880-882．
[7]Wendel C，Hemping-Bovenkerk A，Krasnyanska J，et al．CXCR4/CXCL12 participate in extravasation of metastasizing breast cancer cells within the liver in a rat model［J］．PloS One，2012，7(1)：e30046．
[8]Sakai N，Yoshidome H，Shida T，et al．CXCR4/CXCL12 expression profile is associated with tumor microenvironment and clinical outcome of liver metastases of colorectal cancer［J］．Clinical & Experimental Metastasis，2012，29(2)：101-110．
[9]Chrostek L，Cylwik B，Panasiuk A，et al．Lipid-bound sialic acid(LSA) in liver diseases of different etiologies［J］．Annals of Hepatology，2011，10(2)：150-154．
[10]王敏杰，严翠娥，李学祥，等．血清唾液酸在肝癌患者诊疗中的临床应用［J］．中华检验医学杂志，2013，36(7)：643-647． Wang MJ，Yan CE，Li XX，et al．The clinical significance of serum sialic acid detection for diagnosis and therapy monitoring in liver cancer patients［J］．Chin J Lab Med，2013，36(7)：643-647．
[11]季海生，厉波，杨爱，等．血清唾液酸检测在恶性肿瘤诊治中的临床研究［J］．中华全科医师杂志，2010，9(5)：345-346． Ji HS，Li B，Yang A，et al．Serum sialic acid levels in diagnosis and monitoring of malignant tumor［J］．Chin J Gen Pract，2010，9(5)：345-346．
[12]王春燕，刘健，贾玫，等．血清唾液酸检测在妇科恶性肿瘤诊断中的评价［J］．中国实验诊断学，2009，13(10)：1375-1377． Wang CY，Liu J，Jia M，et al．To evaluate the serm level of sialic acid in gynaecological malignant tumors［J］．Chin J Lab Diagn，2009，13(10)：1375-1377．

相似文献/References:

[1]毛丽萍,何义民,韩 刚,等.血浆Dickkopf同源物1检测对肝细胞癌的诊断价值[J].现代检验医学杂志,2016,31(05):62.[doi:10.3969/j.issn.1671-7414.2016.05.016]
　MAO Li-ping,HE Yi-min,HAN Gang,et al.Diagnosis Value of Detecting Plasma Dickkopf-1 Patients with Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2016,31(06):62.[doi:10.3969/j.issn.1671-7414.2016.05.016]
[2]阮瑞杨,陈修荣,赵世元.抗EZH2自身抗体IgG在肝癌患者血清中的表达及意义[J].现代检验医学杂志,2017,32(02):72.[doi:10.3969/j.issn.1671-7414.2017.02.019]
　RUAN Rui-yang,CHEN Xiu-rong,ZHAO Shi-yuan.Expression and Significance of Anti EZH2 Autoantibodies IgG in Hepatocellular Carcinoma Patient's Serum Samples[J].Journal of Modern Laboratory Medicine,2017,32(06):72.[doi:10.3969/j.issn.1671-7414.2017.02.019]
[3]隆绍平,邓世群,赵世元.PTPN12蛋白表达下调与原发性肝细胞癌患者复发和预后关系研究[J].现代检验医学杂志,2018,33(01):86.[doi:10.3969/j.issn.1671-7414.2018.01.001]
　LONG Shao-ping,DENG Shi-qun,ZHAO Shi-yuan.Association between Downregulation of PTPN12 Protein and Recurrence and Prognosis in Patients with Primary Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2018,33(06):86.[doi:10.3969/j.issn.1671-7414.2018.01.001]
[4]毛丽萍,王跃国,王 健,等.CMIA法测定血清DCP与AFP对肝细胞癌的诊断价值[J].现代检验医学杂志,2018,33(06):38.[doi:10.3969/j.issn.1671-7414.2018.06.010]
　MAO Li-ping,WANG Yue-guo,WANG Jian,et al.Diagnostic Value of the Serum DCP and AFP Determined by CMIA in Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2018,33(06):38.[doi:10.3969/j.issn.1671-7414.2018.06.010]
[5]吴良银a,李文丽b,刘 俊a.肝细胞癌患者生存预后相关长链非编码RNA(LncRNA)的生物信息学分析[J].现代检验医学杂志,2019,34(04):18.[doi:10.3969/j.issn.1671-7414.2019.04.005]
　WU Liang-yina,LI Wen-lib,LIU Juna.Bioinformatics Analysis of Long-Chain Non-Coding RNA Related to Survival and Prognosis in Patients with Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2019,34(06):18.[doi:10.3969/j.issn.1671-7414.2019.04.005]
[6]吴良银a,李文丽b,刘　俊b.基于GEO数据的病毒相关性肝癌潜在生物基因标志物的筛选及生物信息学分析[J].现代检验医学杂志,2021,36(06):106.[doi:10.3969/j.issn.1671-7414.2021.06.022]
　WU Liang-yin,LI Wen-li,LIU Jun.Screening and Bioinformatics Analysis of Potential Biomarkers for Virus-associated Hepatocellular Carcinoma Based on GEO Data[J].Journal of Modern Laboratory Medicine,2021,36(06):106.[doi:10.3969/j.issn.1671-7414.2021.06.022]
[7]陈 偲,李忠辉a,王 颖b.miR-198 通过靶向ZEB2 调控EMT 过程抑制肝癌细胞增殖和迁移的机制研究[J].现代检验医学杂志,2022,37(04):23.[doi:10.3969/j.issn.1671-7414.2022.04.005]
　CHEN Si,LI Zhong-huia,WANG Yingb.Study on the Mechanism of miR-198 Inhibiting the Proliferation and Migration of Hepatoma Cells by Regulating EMT Process by Targeting ZEB2[J].Journal of Modern Laboratory Medicine,2022,37(06):23.[doi:10.3969/j.issn.1671-7414.2022.04.005]
[8]王 路,叶 莎,韩 霞,等.循环外泌体miRNA 检测对肝细胞癌临床诊断效能的Meta 分析[J].现代检验医学杂志,2022,37(04):59.[doi:10.3969/j.issn.1671-7414.2021.04.012]
　WANG Lu,YE Sha,HAN Xia,et al.Meta-Analysis of the Diagnostic Value of Circulating Exosomes miRNA Detection for Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2022,37(06):59.[doi:10.3969/j.issn.1671-7414.2021.04.012]
[9]时晓晓a,董 翔a,于若卉b,等.miR-203a-3p 靶向GLS1 调控HCC 细胞增殖、迁移、侵袭的机制研究[J].现代检验医学杂志,2022,37(05):86.[doi:10.3969/j.issn.1671-7414.2022.05.018]
　SHI Xiao-xiaoa,DONG Xianga,YU Ruo-huib,et al.Mechanism of miR-203a-3p Targeting GLS1 to Regulate the Proliferation, Migration and Invasion of HCC Cells[J].Journal of Modern Laboratory Medicine,2022,37(06):86.[doi:10.3969/j.issn.1671-7414.2022.05.018]
[10]吴翠婷,周雪辉,张婉馨.基于生物学信息分析筛选晚期肝细胞癌患者接受PD-1 抑制剂治疗后糖酵解相关基因差异表达并构建生存获益模型与验证[J].现代检验医学杂志,2023,38(05):34.[doi:10.3969/j.issn.1671-7414.2023.05.007]
　WU Cuiting,ZHOU Xuehui,ZHANG Wanxin.Differential Expression of Glycolysis-related Genes in Patients with Advanced Hepatocellular Carcinoma Treated with PD-1 Inhibitors Screened Based on Biological Information Analysis, and Survival Benefit Model Constructed and Verified[J].Journal of Modern Laboratory Medicine,2023,38(06):34.[doi:10.3969/j.issn.1671-7414.2023.05.007]

备注/Memo

备注/Memo:
作者简介：邓旭(1980-)，女，本科，主管护理师，内科护理学，Tel：15609125608，E-mail：1164191646@qq.com。
更新日期/Last Update: 1900-01-01